Abstract
The viral enzyme, HIV integrase (MW 32 kDa), is one of the three key enzymes of the pol gene of HIV. HIV integrase is involved in the integration of HIV DNA into host chromosomal DNA. There is apparently no functional equivalent of this enzyme in human cells. Integration of HIV DNA into the host cell genome apparently occurs by a carefully defined sequence of DNA tailoring (3-processing) and coupling (joining or integration) reactions. In spite of some effort in this area targeted at the discovery of therapeutically useful inhibitors of this viral enzyme, there are no drugs for HIV / AIDS in clinical use where the mechanism of action is inhibition of HIV integrase. It is clear that new knowledge on inhibitors of this enzyme is of critical importance in the anti-HIV drug discovery area. This review focuses on the major classes of compounds that have been discovered as inhibitors of HIV integrase. Some of these compounds are non-specific inhibitors of the enzyme while evidence suggests that others may possess some specificity. The various classes include nucleotides, oligonucleotides, dinucleotides, and miscellaneous small molecules including heterocyclic systems, natural products, diketo acids and sulfones. A major focus of the review is on discoveries from my laboratory in the area of non-natural, nuclease-resistant dinucleotide inhibitors of HIV integrase.
Keywords: hiv integrase, anti-hiv therapeutic agents, pol gene of hiv, hiv/aids, nuclease-resistant dinucleotide inhibitors
Current Pharmaceutical Design
Title: Novel Inhibitors of HIV Integrase: The Discovery of Potential Anti-HIV Therapeutic Agents
Volume: 9 Issue: 31
Author(s): Vasu Nair
Affiliation:
Keywords: hiv integrase, anti-hiv therapeutic agents, pol gene of hiv, hiv/aids, nuclease-resistant dinucleotide inhibitors
Abstract: The viral enzyme, HIV integrase (MW 32 kDa), is one of the three key enzymes of the pol gene of HIV. HIV integrase is involved in the integration of HIV DNA into host chromosomal DNA. There is apparently no functional equivalent of this enzyme in human cells. Integration of HIV DNA into the host cell genome apparently occurs by a carefully defined sequence of DNA tailoring (3-processing) and coupling (joining or integration) reactions. In spite of some effort in this area targeted at the discovery of therapeutically useful inhibitors of this viral enzyme, there are no drugs for HIV / AIDS in clinical use where the mechanism of action is inhibition of HIV integrase. It is clear that new knowledge on inhibitors of this enzyme is of critical importance in the anti-HIV drug discovery area. This review focuses on the major classes of compounds that have been discovered as inhibitors of HIV integrase. Some of these compounds are non-specific inhibitors of the enzyme while evidence suggests that others may possess some specificity. The various classes include nucleotides, oligonucleotides, dinucleotides, and miscellaneous small molecules including heterocyclic systems, natural products, diketo acids and sulfones. A major focus of the review is on discoveries from my laboratory in the area of non-natural, nuclease-resistant dinucleotide inhibitors of HIV integrase.
Export Options
About this article
Cite this article as:
Nair Vasu, Novel Inhibitors of HIV Integrase: The Discovery of Potential Anti-HIV Therapeutic Agents, Current Pharmaceutical Design 2003; 9 (31) . https://dx.doi.org/10.2174/1381612033453703
DOI https://dx.doi.org/10.2174/1381612033453703 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Solvent-Free and Self-Catalyzed Three-Component Synthesis of Diversely Substituted Pyrazolo[1,4]thiazepinones of Potential Antitumor Activity
Current Organic Synthesis The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Advanced Micro-Nano-Bio Systems for Future Targeted Therapies
Current Nanoscience Modeling and Simulation Approach to Support Dosing and Study Design Requirements for Treating HIV-Related Neuropsychiatric Disease with the NK1-R Antagonist Aprepitant
Current HIV Research Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Feature Clustering and Ensemble Learning Based Approach for Software Defect Prediction
Recent Advances in Computer Science and Communications Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology Isolation, Synthesis and Biomimetic Reactions of Metalloporphyrinoids in Ionic Liquids
Current Organic Synthesis Melamine Derivatives - A Review on Synthesis and Application
Current Organic Synthesis The Use of Keratin in Biomedical Applications
Current Drug Targets Synthetic Androgens as Designer Supplements
Current Neuropharmacology Advances and Perspectives in Cell-Specific Aptamers
Current Pharmaceutical Design Bergenin - A Biologically Active Scaffold: Nanotechnological Perspectives
Current Topics in Medicinal Chemistry Sugar-Borate Esters – Potential Chemical Agents in Prostate Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Wound Healing Effects of Curcumin: A Short Review
Current Pharmaceutical Biotechnology Discovery of New Therapeutic Targets by the Informational Spectrum Method
Current Protein & Peptide Science Pain-Relief Medication and Risk of Fractures
Current Drug Safety Metformin Protects the Brain Against the Oxidative Imbalance Promoted by Type 2 Diabetes
Medicinal Chemistry A Survey of Metrics Measuring Difference for Rooted Phylogenetic Trees
Current Bioinformatics 2, 7-Diarylidene-cycloheptanone, Hydrazonoyl Chlorides and Heterocyclic Amines as Precursors for Synthesis of Bioactive new Fused Cycloheptapyrimidine Derivatives
Current Organic Synthesis